Corcept Therapeutics (CORT) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 10, 2025, to elect nine directors, ratify the auditor, and hold an advisory vote on executive compensation.

• Only stockholders of record as of April 17, 2025, are eligible to vote; 106,044,683 shares outstanding.

• Key 2024 achievements include revenue growth to $675M, clinical trial progress, and a new drug application submission.

Voting matters and shareholder proposals

• Proposals include electing nine directors, ratifying Ernst & Young LLP as auditor, and an advisory vote on executive compensation.

• Board recommends voting in favor of all proposals.

• Shareholder proposals for the 2026 meeting must be submitted by December 31, 2025.

Board of directors and corporate governance

• Board consists of nine nominees, eight of whom are independent; CEO is not independent.

• Committees: Audit, Compensation, and Corporate Governance & Nominating, all composed of independent directors.

• Board leadership separates CEO and Chairman roles; regular risk oversight and annual strategic review.

• Directors attended at least 75% of meetings; seven attended the last annual meeting.